← Back to Search

Procedure

Trigger Point Injections for Myofascial Pain

Phase 2
Waitlist Available
Led By Mohab Ibrahim, Md., Ph.D
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of myofascial pain
Failed conservative therapy or unable to participate in physical therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights

Study Summary

This trial will help to determine how many needle passes are necessary to achieve pain control for myofascial pain patients.

Who is the study for?
This trial is for English-speaking individuals with myofascial pain who haven't found relief through conservative treatments or can't do physical therapy. It's not suitable for those with serious mental illnesses that affect pain perception or conditions causing widespread pain.Check my eligibility
What is being tested?
The study tests how many needle passes in trigger point injections (using lidocaine and bupivacaine) are best for relieving chronic muscle pain. Participants will be randomly assigned to receive either 2, 10, or 20 needle passes at a clinic in Tucson, Arizona.See study design
What are the potential side effects?
Possible side effects from the injections may include temporary discomfort at the injection site, bruising, bleeding, allergic reactions to the anesthetics used (lidocaine and bupivacaine), and rarely nerve damage.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with muscle pain.
Select...
Physical therapy did not work for me or I cannot do it.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in pain intensity
Secondary outcome measures
Change in Sleep patterns
Perceived Subjective Changes in the Ability to Work, Do Chores, and Exercise.

Trial Design

3Treatment groups
Active Control
Group I: One to two needle passesActive Control1 Intervention
Receive 1-2 needle passes for needling at each trigger point
Group II: Ten needle passesActive Control1 Intervention
Receive 10 needle passes for needling at each trigger point
Group III: Twenty needle passesActive Control1 Intervention
Receive 20 needle passes for needling at each trigger point

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
514 Previous Clinical Trials
147,971 Total Patients Enrolled
Mohab Ibrahim, Md., Ph.DPrincipal InvestigatorUniversity of Arizona

Media Library

Trigger Point Injection (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04732507 — Phase 2
Myofascial Pain Syndrome Research Study Groups: One to two needle passes, Ten needle passes, Twenty needle passes
Myofascial Pain Syndrome Clinical Trial 2023: Trigger Point Injection Highlights & Side Effects. Trial Name: NCT04732507 — Phase 2
Trigger Point Injection (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04732507 — Phase 2
Myofascial Pain Syndrome Patient Testimony for trial: Trial Name: NCT04732507 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research undertaking currently admitting new participants?

"According to clinicaltrials.gov, this research is no longer open for enrollment; its initial posting was on April 20th 2021 and the most recent update took place on October 3rd 2022. Despite not actively searching for participants anymore, 296 other trials are still seeking candidates at present."

Answered by AI

What medical procedure is commonly conducted with the utilization of one to two needle passes?

"Needling is a common practice for treating minor burns, however this technique can also be leveraged to help manage lupus erythematosus cell, ulcerative colitis, and transplantation."

Answered by AI

Does the U.S. Food and Drug Administration endorse a protocol of 1-2 needle passages for this procedure?

"Based on the available safety data, our team at Power assigned a rating of 2 to one or two needle passes due to it being in Phase 2 which suggests some evidence for its security but none for efficacy."

Answered by AI

Have any other investigations explored the efficacy of a single or double puncture approach?

"Presently, 214 live clinical trials are examining the efficacy of One to two needle passes. Of those studies, 48 have reached Phase 3. The bulk of these investigations are based in Germantown Tennessee; however, 1125 locations worldwide are also conducing research into this treatment modality."

Answered by AI

How many participants are currently partaking in this clinical experiment?

"This specific trial is no longer recruiting patients. It was first posted on April 20th 2021 and its last update took place on October 3rd 2022. Currently, 82 trials are seeking participants with pain and 214 for One to two needle passes."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
What site did they apply to?
Banner University Medical Center Multispecialty Services Clinic
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

No one will prescribe me pain medication and I can't do daily activities. I need an alternative and if this helps me and others like me I'm happy to be part of the trial.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome
Mohab Ibrahim, PhD MD 2021. "Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04732507.
All > Lidocaine > Exparel
~75 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top